Close menu

December 23rd, 2020 | 08:50 CET

Q & M Dental, Moderna, AstraZeneca: Serving people!

  • Health
Photo credits: Q & M Dental Group

Rarely has the stock market been so focused on people as it has been during the pandemic. People are thinking about which companies offer the best service package for all the problems associated with infections, vaccinations and even the psychological effects of isolation and loneliness. Humans are "social animals" with multiple social needs. Curtailing these needs works temporarily, but at some point, the arguments have to be genuinely purposeful so that certain restrictions continue to be accepted. At the peak of the contagion curve, we would like to see possible remedies that quickly turn the overall situation into a positive end - this is possible for the medium-term future. Still, in the short term, we have to stick together.

time to read: 4 minutes | Author: André Will-Laudien
ISIN: SG2E73981531 , US60770K1079 , GB0009895292

Table of contents:

    Q & M Dental Group - Asian health care player grows properly

    Q & M Dental Group is a Singapore-based dental service provider with its main product Invisalign, which is also successfully used in Europe to correct misaligned teeth. In addition to Europe and the USA, the market is also growing strongly in Asia at around 12% per year. Together with its subsidiaries, the group is a leading private dental service provider in Singapore with a growth of over 20% per annum.

    Expansion plans are already in place for Malaysia, the People's Republic of China and other ASEAN countries. Currently, they operate 114 dental clinics, 5 medical clinics and 3 dental supplies and equipment distribution companies. Supported by more than 230 experienced dentists and nearly 400 employees, the group has more than 300,000 patients in Singapore. In addition to general and specialized dental and medical care, the group has also invested in postgraduate training with the establishment of the Q & M School.

    Since April this year, it has also been offering tools for Covid-19 testing centers together with its partner Acumen Diagnostics. As a result, revenue shortfalls during lockdown periods can be bridged in the best possible way. Revenue will reach about 128 million Singapore dollars (SGD) in 2020, with pre-tax profit adding up to SGD 20 million. The share price has already moved decently this year between SGD 0.30 and SGD 0.73. At the current price of SGD 0.46, the market capitalization is SGD 362 million. With these growth figures, Q & M is therefore not too expensive. Admittedly, it needs accessible practices to deliver services to patients unimpeded again, so one should expect the share price to pick up nicely by summer at the latest.

    Moderna - vaccine in the approval phase

    Moderna Inc. is a US biotech Company specializing in the research and development of drugs based on mRNA. mRNA drugs are designed to enable the body's cells to produce proteins with therapeutic or preventive effects that can help treat various diseases. Applications for mRNA products include therapeutics and vaccines for cancer immunotherapies, rare diseases, cardiovascular diseases, autoimmune diseases and inflammation. The Company's consistent progress in basic and applied mRNA research enables parallel new developments, both independently and with strategic partners.

    In the US, the first people were administered the US Company Moderna's Corona vaccine on Monday. CNN television showed doses of the vaccine being administered at a hospital in Houston, Texas. On the short messaging service Twitter, hospitals in Ohio and Connecticut, among others, posted photos of doctors and nurses receiving the vaccine. The United States is the first country in the world to use the substance away from testing. Before the end of the year, 20 million units could be available in the US, according to the Company; in Europe, a meeting on possible approval is set for Jan. 6, 2021.

    According to analyst estimates, Moderna Inc. is expected to climb from 2019 sales of USD 60 million to more than USD 500 million this year, and USD 7 billion in 2021 because of the pandemic. Profits could explode to about USD 2 billion next year, giving the Company a P/E ratio of just 22 on a capitalization of USD 44 billion. Currently, it is not yet making a profit. The share price has already risen by 600% in the last 12 months.

    AstraZeneca - pharmaceutical giant may soon deliver

    AstraZeneca plc is a Swedish-British Pharmaceutical Company engaged in the development, production and marketing of prescription drugs. AstraZeneca's research focuses primarily on respiratory, cardiovascular and metabolic, cancer, inflammatory, infection and neurological disorders. The Company offers medicines for asthma, heart attacks, breast and prostate cancer, diabetes, and the treatment of depression, schizophrenia, and bipolar disorder. The Company was formed in 1999 through the Swedish group Astra's merger, founded back in 1913, with the British Company Zeneca.

    The UK Medicines and Healthcare products Regulatory Agency (MHRA) has not yet decided whether to approve the Covid-19 vaccine. The review is ongoing to ensure that any approved vaccine meets the expected high safety standards, quality and efficacy. Previously, the Daily Telegraph reported that the vaccine, which AstraZeneca is developing in collaboration with the prestigious University of Oxford, should receive approval before the end of December. Unfortunately, we are not there yet. Meanwhile, a mutation of the Covid-19 virus has already emerged on the island, and the EU is responding with travel measures.

    The European Union has already ordered several 100 million doses from AstraZeneca. In total, billions of doses have already been ordered worldwide. The promising active ingredient AZD1222 is based on an attenuated version of a cold virus from chimpanzees. It contains the genetic material of a surface protein with which the pathogen Sars-CoV-2 attaches to human cells. The drug has a twofold effect: it promotes the formation of both specific antibodies and T cells - both of which are important for immune defense.

    AstraZeneca plc is among the 10 largest pharmaceutical companies globally, with a market capitalization of a whopping GBP 100 billion. The turnover is about GBP 22 billion, the bottom-line profit is GBP 3.5 per share, so the P/E ratio is about 20. In contrast to its industry peers, AstraZeneca lost about 5% over the year - but there is a 2.8% dividend.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 22nd, 2022 | 11:58 CEST

    Cardiol Therapeutics, Apple, Nel - Crisis-proof shares, despite inflation

    • Biotechnology
    • Covid19
    • Health

    Heart fluttering, pulse racing among investors, share prices highly volatile due to FED measures. Inflation and recessionary times are brutal for investors in the capital market. Three candidates have the potential to become profitable long-term investments: Cardiol Therapeutics, Apple and Nel. Cardiol Therapeutics fills the gap in the pharmaceutical market for the treatment of the heart disease, myocarditis. Apple is increasingly focusing on monitoring heart health, as cardiovascular disease is one of the leading causes of death in industrialized nations. In turn, these nations are struggling with extremely high energy prices. No wonder, then, that the Norwegian government is financially supporting the Company Nel to produce green hydrogen as quickly as possible...


    Commented by Nico Popp on November 25th, 2021 | 11:46 CET

    BB Biotech, Sativa Wellness, Carnival: Anti-aging as a megatrend

    • Health

    Anti-aging medicine is one of the most exciting research topics of our time. Already in 2018, Citigroup named the field as one of the ten rising topics of the future. While the pandemic has obscured many long-term ventures in the media, the work continues. People have long been optimizing and working to feel at least a little younger. We present three stocks related to biotechnology, anti-aging and wellness.


    Commented by Stefan Feulner on February 9th, 2021 | 08:00 CET

    CureVac, Cardiol Therapeutics, Bayer - roaring profits!

    • Health

    The race for the best and most effective vaccine is in full swing. After BioNTech and its partner Pfizer, Moderna and AstraZeneca were approved in Europe, but there are always obstacles. Over the weekend, for example, South Africa announced that it is forgoing the AstraZeneca vaccine for the time being. The background to this is its supposedly lower efficacy with the B.1.351 virus mutation. Somewhat unnoticed, another vaccine manufacturer is moving into pole position through innovative collaborations.